You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Epidermal growth factor receptor (EGFR) mutations

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in

Recruiting
  • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 21, 2023

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

Recruiting
  • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 25, 2023

NSCLC Trial (Mobocertinib 160 mg)

Approved for marketing
  • Carcinoma, Non-Small-Cell Lung
  • Mobocertinib 160 mg
  • (no location specified)
Sep 28, 2022

Recurrent/Advanced Gastric Cancer Trial in Seoul (Chemotherapy)

Not yet recruiting
  • Recurrent/Advanced Gastric Cancer
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Aug 22, 2022

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • NSCLC
  • (no location specified)
Jul 17, 2022

NSCLC (NSCLC) Trial (Dacomitinib+Anlotinib, Dacomitinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Feb 28, 2022

Lazertinib Trial in Suwon-si, Goyang-si, Seoul (Lazertinib, Bevacizumab Injectable Product)

Recruiting
  • Lazertinib
  • Suwon-si, Gyeonggi-do,, Korea, Republic of
  • +4 more
Nov 27, 2023

Epidermal Growth Factor Receptor Mutations in Advanced EGFR

Completed
  • Non Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Dec 22, 2020

NSCLC Trial in Badalona, Málaga (Docetaxel, Cisplatin, Gemcitabine)

Completed
  • Non-small Cell Lung Cancer
  • Badalona, Barcelona, Spain
  • +1 more
Jun 8, 2022

NSCLC Stage II, NSCLC, Stage IIIA Trial in Goyang-si (Erlotinib)

Active, not recruiting
  • NSCLC Stage II
  • NSCLC, Stage IIIA
  • Goyang-si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

Observational Study of Afatinib 30 mg Daily

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Epidermal Growth Factor Receptor Mutation
  • Singapore, Singapore
    Nationa University Hospital
Apr 4, 2022

EGFR Positive NSCLC Trial in Goyang-Si (Erlotinib plus Bevacizumab, Erlotinib)

Active, not recruiting
  • EGFR Positive Non-small Cell Lung Cancer
  • Goyang-Si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Mar 24, 2023

NSCLC Trial (Aumolertinib, Placebo Aumolertinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
Jun 10, 2021

NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • (no location specified)
Mar 27, 2023

GIOTRIF rPMS in Korean Patients With NSCLC

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • GIOTRIF 20mg
  • +2 more
  • Multiple Locations, Korea, Republic of
    (unnamed)
Feb 5, 2021

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • (no location specified)
Aug 10, 2023

Non Small Cell Lung Cancer Trial in Durham (Atezolizumab, Bevacizumab)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • Durham, North Carolina
    Duke University Medical Center
May 23, 2022

NSCLC With EGFR-Activating Mutations Trial in Worldwide (Dacomitinib (PF-00299804), Gefitinib)

Completed
Has Results
  • Non-small Cell Lung Cancer With EGFR-Activating Mutations
  • Beijing, China
  • +51 more
Feb 10, 2022

NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

Not yet recruiting
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • (no location specified)
Aug 27, 2023

Metastatic Non Small Cell Lung Cancer Trial in India (Dacomitinib)

Active, not recruiting
  • Metastatic Non Small Cell Lung Cancer
  • New Delhi, Delhi, India
  • +13 more
Jan 20, 2022

Pancreatic Adenocarcinoma, Lung Cancer Trial in Truro (Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF

Unknown status
  • Pancreatic Adenocarcinoma
  • Lung Cancer
  • Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF mutations in liquid based cytology and blood plasma samples
  • Truro, Cornwall, United Kingdom
    Royal Cornwall Hospital
Feb 26, 2021

EGFR Mutation-Related Tumors Trial (NX-019)

Not yet recruiting
  • EGFR Mutation-Related Tumors
  • (no location specified)
Aug 22, 2022

Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T

Not yet recruiting
  • Recurrent Glioblastoma
  • Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
  • (no location specified)
Apr 4, 2023

PFS Trial in Qingdao (afatinib)

Recruiting
  • PFS
  • Qingdao, Shandong, China
  • +1 more
Feb 23, 2022